| abstract |
The present invention relates to a pharmaceutical composition for the treatment of diabetes mellitus, comprising insulin and a double agonist of the glucagon-like peptide of type 1 (GLP-1 / glucagon) where the insulin is of the natural type, fast-acting. , among other; Insulin and GLP-1 / glucagon are long acting and the biocompatible material capable of extending the duration of the activation of the composition, is linked by a linker or covalent bond, in addition the composition is linked by a non-peptidyl polymer linker to an immunoglobulin Fc region belonging to FcRn; GLP-1 / glucagon is SEQ ID NO 40 and the amino acids at positions 16 and 20 form a ring. This composition can inhibit weight gain and reduce the danger of hypoglycemia |